Floatz logo

Kite-363

Myasthenia Gravis

Kite, A Gilead CompanyCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Myasthenia Gravis cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Fred Hutchinson Cancer Center
Phase 2CCC
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2CCC
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 2CCC
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2CCC
CARMUSTINE
Fred Hutchinson Cancer Center
Phase 2CCC

View all 22 →

Same molecule, other indications

Kite-363 is also rated in:

B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
chronic inflammatory demyelinating polyradiculoneuropathyDormant
CC
Indicative ·
43 / 100
View asset →
multiple sclerosisDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →